INTRODUCTION
Genome-wide association studies (GWAS) have identified more than 50 common variants associated with susceptibility to prostate cancer (PrCa). However, these variants explain less than a third of the familial risk of the disease, indicating that further susceptibility loci remain to be identified. Moreover, few variants identified by GWAS have thus far been 410
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shown to be associated with aggressive PrCa. Although the current set of SNPs contributes to overall PrCa risk prediction, overall they do not discriminate men who will develop aggressive disease, a clinically more relevant outcome. A recent GWAS of aggressive PrCa identified a novel susceptibility locus on 2q37.3, but the per-allele odds ratio (OR) did not differ between aggressive and non-aggressive cases in the replication stage (1) . It has been also reported that a genetic variant in DAP2IP might be associated with the risk of aggressive PrCa (2) . A recent GWAS and validation study of aggressive PrCa found an SNP on 15q13, rs6497287, to be uniquely associated with this disease trait (P replication ¼ 0.004); however, lack of power due to small numbers and a nonsignificant test for heterogeneity between less and more aggressive PrCa warrants further investigation of this finding (3) . Lin et al. (4) have reported an association of PrCa mortality with five germline SNPs from a candidate gene analysis.
RESULTS
In an attempt to identify susceptibility loci for aggressive PrCa, we conducted a meta-analysis of four GWAS (Table 1 and Supplementary Material, Notes). We also included data from the second stage of the UK study, that was genotyped for 43 671 SNPs showing evidence for association in stage 1 (5) . These studies included, after quality control (QC) exclusions (see Materials and Methods), a total of 11 463 controls and 11 085 cases. For the present analysis, we included data from 5953 cases with aggressive disease defined as having a Gleason score of 8 or greater (with the exception of the BPC3 study, which also includes cases with tumor stage C or greater, and the CGEMS study, which also included cases with a Gleason score of 7) and all controls (it was ensured that there was no overlap between the studies). Following imputation using HapMap Phase II CEU as a reference, approximately 2.6 million genotyped and imputed SNPs were assessed in each GWAS study using a 1 df trend tests for association. Combined association tests were generated using a fixed effects meta-analysis (see Materials and Methods).
In the combined analysis, two loci, rs11672691 on 19q13 (P-value ¼ 3.8 × 10 27 ) and rs11704416 on 22q13 (P ¼ 7.0 × 10 26 ), showed strong evidence for association. rs11672691 is in the same region as rs887391 (r 2 ¼ 0.9) that it was previously reported to be associated with PrCa by Hsu et al. (6) , but it did not reach GWAS significance level in that report. These two SNPs were selected for further replication analysis in two international consortia, PRACTICAL and BPC3. The present analysis was restricted to 24 395 cases (2008 aggressive) and 24 726 controls (17 445 controls in aggressive disease analysis) from 26 studies from European populations ( Table 1 , Supplementary Material, Table S1 and Supplementary Material, Notes show all 29 studies, 26 of which are European).
SNP rs11672691 showed evidence of replication (P ¼ 0.006) with a genome-wide significance of P ¼ 1.4 × 10 28 in a combined analysis across all stages ( Table 2) for aggressive PrCa. When data from non-aggressive cases were also included, the overall evidence for association was stronger (P ¼ 2.2 × 10 212 , overall). The per-allele OR for aggressive PrCa in the replication stage [1.12, 95% confidence interval (CI) 1.03 -1.21; P ¼ 0.006] was higher than that for nonaggressive cases (OR 1.08, 95% CI 1.05-1.12; P ¼ 8.2 × 10 27 ); however, the difference was not statistically significant (P-value ¼ 0.18). SNP rs11704416 showed evidence of replication for all PrCa (P ¼ 0.002), but did not quite reach genome-wide significance overall (P ¼ 3.7 × 10 27 ). The evidence for association with aggressive disease was weaker (P ¼ 0.16 in the replication, P ¼ 4.0 × 10 26 overall). There was no evidence that either locus was associated with serum PSA (based on 1578 control samples; Supplementary Material, Table S2 ). SNP rs11672691 showed stronger effect (P ¼ 0.02) when we compared cases with a family history of PrCa (OR 1.14, 95% CI 1.06-1.22) with those with no family history (OR 1.06, 95% CI 1.02 -1.10). The per-allele ORs did not differ significantly by ages (Supplementary Material, Table S3 ). Considering the estimated ORs in the replication stage, rs11672691 and rs11704416 together explain 0.16% of the familial risk of PrCa.
DISCUSSION
rs11672691 lies between ATP5SL and CEACAM21 ( Fig. 1A ) and within a hypothetical locus, LOC100505495, of a noncoding RNA. ATP5SL codes for an ATP synthase-like protein whose function is unknown; however, a variant in this gene has been associated with adult height (7) . The carcinoembryonic antigen (CEA) gene family belongs to the immunoglobulin super family of genes. Several CEA subgroup members possess cell adhesion properties and some seem to function in signal transduction or regulation of signal transduction, possibly in association with other CEA sub-family members (8) . Several of these proteins show a complex expression pattern in normal and cancerous tissues. Both CEACAM5 and CEACAM6 have a role in cell adhesion, invasion and metastasis (9) , and are known to be overexpressed in a majority of carcinomas, including those of the gastrointestinal tract, the respiratory and genitourinary systems and breast cancer. The closest gene, CEACAM21, has been considered as a candidate gene for type 1 diabetes (10) . A region on 19q13 (HPCQTL19) has been reported previously in a genetic linkage study to be a QTL for aggressive PrCa when the Gleason score was used as a quantitative measure of tumor aggressiveness (11) . SNP rs11704416 lies upstream of TNRC6B on chromosome 22 (Fig. 1B) . The TNRC6 (trinucleotide repeat containing 6) family of proteins have been shown to stably associate with argonaute (AGO) proteins. AGO proteins, through their association with small RNAs, perform a critical function in the effector step of RNA interference. TNRC6B protein has a role in translational inhibition through its binding to AGOs (12) .
These results illustrate the value of combining GWAS to confirm candidate loci where the genome-wide significance threshold was not obtained, and improve power identifying susceptibility loci associated with sub-classifications of diseases. The original report by Hsu et al. (6) implicating the 19q13 region failed to reach genome-wide significance, whereas our findings verify a significant association. Although some samples overlap between the Hsu et al. report and our study, we expanded the discovery phase by incorporating the Stage 1 UK and Stage 2 UK/Melbourne participants and including additional samples in the replication stage. The identification of loci involved in PrCa aggressiveness has been hampered by relatively small sample sizes. The locus reported here is associated with both aggressive and non-aggressive diseases, and is therefore likely to be useful in determining those with clinically significant PrCa. Identification of such loci would aid the understanding of the biology of PrCa progression and targeted screening based on genetic risk profiling for aggressive disease.
MATERIALS AND METHODS

Samples
The four GWAS data sets have been described previously (1, 5, 13, 14) (Table 1 ). Analyses were based on the data sets following standard QC procedures as previously described (5) . The replication stage included 25 072 cases (2160 cases with a Gleason score of 8+) and 25 536 controls (18 255 in aggressive disease analysis) from 29 PrCa case-control studies (Supplementary Material, Table S1 and Notes). All studies were approved by the appropriate ethics committees.
Genotyping
In BPC3 and PRACTICAL, genotyping of samples from 13 studies was performed by the KASPar assay Table S4 . Assays at all sites included at least four negative controls and 2 -5% duplicates on each 384-well plate. QC guidelines were followed by all the participating groups as described previously. In addition, all sites also genotyped 16 CEPH samples. We excluded individuals whose genotypes failed for at least 20% of the SNPs attempted. Data on a given SNP for a given site had to fulfill the following to be included: SNP call rate .95%, no deviation from Hardy -Weinberg equilibrium in controls at P , 0.00001, ,2% discordance between genotypes in duplicate samples and in the CEPH samples. Cluster plots for SNPs that were close to failing any of the QC criteria were re-examined centrally.
Statistical methods
Imputation
Genotypes were imputed for approximately 2.6 million SNPs using the HapMap phase 2 CEU population as a reference. UK stages 1 and 2 and CGEMS were imputed using MACH 1.0 (http://www.sph.umich.edu/csg/abecasis/MACH/) to impute genotypes of autosomal markers and IMPUTE v1 (15) for chromosome X. The imputation for the BPC3 study was performed using MACH 1.0. The CAPS study used IMPUTE v1. We included imputed data from an SNP in the combined analysis if the estimated correlation between the genotype scores and the true genotypes (r 2 ) was .0.3 (MACH) or where the quality information was .0.3 (IMPUTE).
Analyses
For UK stages 1 and 2 and CGEMS, the imputed genotype probabilities were used to derive a 1 df association score statistic for each SNP, and its corresponding variance. The test statistic for UK stage 2 was stratified by population as described previously (5) . In the BPC3 study, estimated betas and standard errors were calculated for each component study, including one principal component as a covariate to adjust for population structure, using ProbABEL (16) , and the results were combined to generate overall betas and standard errors, using a fixed effects meta-analysis. CAPS used SNPTEST (https://mathgen.stats.ox.ac.uk/genetics_software/ snptest/snptest.html) to estimate betas and standard errors. We converted the results from all studies into test scores and variances and derived a combined x 2 trend statistic for each SNP (equivalent to the Mantel extension test, or as in a fixed effects meta-analysis) in the R package. We repeated the same procedure to combine the results for the case/ control association analysis and aggressive case/control association analysis.
We assessed associations between each SNP and PrCa in the replication stage, using a 1 df Cochran -Armitage trend test stratified by study. The combined P-values over all stages were generated similarly (using a 1 df trend test based on summing the scores and variances from each stage). SNPs were selected for validation on the basis of a significance level of P , 10 27 in a combined meta-analysis of UK stages 1 and 2, CGEMS, CAPS and BPC3, excluding SNPs that were correlated with known susceptibility SNPs (SNP rs11704416 was included since it reached P , 10 27 in an initial analysis). A total of 1921 subjects of non-European ancestry (Asian and African-American) were excluded from all analyses. Analyses were performed based on 2008 aggressive disease PrCa cases (out of 24 395 cases) and 17 445 controls (out of 24 726 controls). OR and 95% CI were estimated using unconditional logistic regression, stratified by study. In the text, we have reported the combined tests of association over all stages in European populations, but have emphasized the OR estimates from the replication stage to minimize the effect of 'winner's curse'. ORs were computed separately for subsets of cases defined by family history, grade and age. Modification of the ORs by family history and grade was assessed using a case-only analysis, using the dichotomous variable as the endpoint (family history Yes versus No/ Grade GS , 8 versus GS ≥ 8). Modification of the ORs by grade as a continuous covariate, and by age, was assessed using a case-only analysis, using polytomous regression with SNP genotype (scored 0, 1, 2) as the endpoint. The associations between SNP genotypes and PSA level were assessed using linear regression after log-transformation of PSA level to correct for skewness. We performed analyses for both all cases and only aggressive cases of PrCa. Analyses were performed in R principally using GenABEL (17) , SNPTEST and ProbABEL (16) and Stata.
